GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » EBIT

Venus Medtech (Hangzhou) (HKSE:02500) EBIT : HK$-735.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) EBIT?

Venus Medtech (Hangzhou)'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$-364.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Venus Medtech (Hangzhou)'s annualized ROC % for the quarter that ended in Dec. 2023 was -14.52%. Venus Medtech (Hangzhou)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -73.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Venus Medtech (Hangzhou)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -29.12%.


Venus Medtech (Hangzhou) EBIT Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) EBIT Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -414.53 -217.75 -459.97 -1,241.48 -735.70

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -317.66 -267.27 -986.86 -370.96 -364.74

Competitive Comparison of Venus Medtech (Hangzhou)'s EBIT

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s EV-to-EBIT falls into.



Venus Medtech (Hangzhou) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-735.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Medtech (Hangzhou)  (HKSE:02500) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Venus Medtech (Hangzhou)'s annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-528.972 * ( 1 - 0.59% )/( (3575.385 + 3665.419)/ 2 )
=-525.8510652/3620.402
=-14.52 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5468.44 - 303.611 - ( 1589.444 - max(0, 692.659 - 2303.75+1589.444))
=3575.385

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4827.627 - 307.271 - ( 854.937 - max(0, 880.676 - 1758.87+854.937))
=3665.419

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Venus Medtech (Hangzhou)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-729.484/( ( (542.235 + max(265.909, 0)) + (765.965 + max(416.179, 0)) )/ 2 )
=-729.484/( ( 808.144 + 1182.144 )/ 2 )
=-729.484/995.144
=-73.30 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(439.286 + 128.856 + 5.692) - (303.611 + 0 + 4.314)
=265.909

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(317.86 + 123.534 + 314.369) - (307.271 + 0 + 32.313)
=416.179

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Venus Medtech (Hangzhou)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-735.702/2526.489
=-29.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Medtech (Hangzhou) EBIT Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Traded in Other Exchanges
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines